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Abstract 
Shigellosis is one of the leading causes of diarrhea worldwide with more than 165 
million cases annually. Hence, a vaccine against this disease is a priority, but no 
licensed vaccine is still available. Considering target population as well as intrinsic risks 
of live attenuated vaccines, non-living strategies appear as the most promising 
candidates. Remarkably, the preservation of antigenic properties is a major concern 
since inactivation methods of bacteria affect these qualities. We previously reported the 
use of a subcellular antigen complex for vaccination against Shigellosis, based on outer 
membrane vesicles (OMVs) released from Shigella flexneri. Now, we describe in more 
detail the employment of binary ethylenimine (BEI) for inactivation of Shigella and its 
subsequent effect on the antigenic conservation of the vaccinal product. Results 
demonstrate the effectiveness of BEI treatment to completely inactivate Shigella cells 
without disturbing the antigenicity and immunogenicity of the OMVs. Thus, OMVs 
harvested after BEI inactivation were able to protect mice against an experimental 
infection with S. flexneri. 
 
Keywords: Shigella; subunit vaccine; safety; outer membrane vesicles 
 
 
 
 3 
 
 
1. Introduction 
Diarrheal diseases are the major causes of morbidity and mortality in the developing 
world [1]. Among them, shigellosis is one of the most contagious types of diarrhea 
caused by bacteria. Shigella spp, the causative agent, invades the intestinal mucosa, 
spreads to the adjacent epithelial cells and causes tissue damage, fluid secretion and 
inflammation, producing the clinical manifestations of dysentery, diarrhea with blood 
and mucus [2]. Shigellosis is endemic throughout the world where it is responsible for 
more than 165 million cases of severe dysentery annually, the majority of which occur 
in children under 5 years old in the developing world [3]. In addition, about 500 000 
cases of shigellosis are reported each year among travellers from industrialized 
countries and military personnel [4]. In the absence of an existing effective vaccine and 
the ever-increasing frequency of antimicrobial-resistant Shigella strains worldwide, 
Shigellosis has become a major source of concern [5]. Several candidate shigellosis 
vaccines are currently in development including live attenuated, inactivated whole cell, 
or subunit vaccines [6-8]. Considering intrinsic risk of living vaccines, the non-living 
vaccine alternative, including either inactivated whole-cell or acellular approaches, 
results the safest direction. However, even being inactivated the final vaccine product, 
the production process managing alive Shigella cells is a risk that should be controlled, 
considering this pathogen is one of the most common causes of laboratory-acquired 
infections [9;10]. Besides, outbreaks of disease have occurred in the past due to 
improper inactivation [11;12]. Considerable knowledge has been accumulated regarding 
the efficiency of microbicidal treatments but, at the same time, the preservation of 
immunogenicity and native structure during production may limit their potential due to 
the alteration of epitopes that may be essential to confer protection. Thus, most used 
treatments, such as heat, acetone, phenol or formaldehyde, cause membrane damage or 
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induce cross-linking of proteins leading to antigenic alterations and consequent failure 
in the ability to elicit protective immunity [13-21]. Here, we evaluate binary 
ethylenimine (BEI) alone or in combination with formaldehyde (BEI-FA) as 
inactivating agent against Shigella cells viability. BEI is an alkylating substance specific 
for the nucleic acids widely used in virus vaccine production [22]. In contrast to some 
other biocides, BEI intercalates with nucleic acids and does not react with proteins, so it 
is not expected to alter their immunogenic properties.  
In the context of subunit vaccines, OMV are attractive candidates by itself and for 
vaccine delivery platforms. OMVs are spherical lipid bilayer blebs with an average 
diameter of 50-250 nm that are naturally secreted by Gram-negative bacteria [23]. 
OMVs encase outer membrane and periplasmic constituents, and function in diverse 
roles such as biofilm formation and virulence. Thus, contain significant immunogens 
and appear to be safe when used as vaccines [24]. Currently, an OMV-vaccine is being 
successfully used against serogroup B meningococcal disease [25;26] and it also 
represents a promising vaccine candidate for several other pathogens like Pseudomonas 
[27], Vibrio [28], Salmonella [29] or Acinetobacter baumannii [30].  
We have previously demonstrated the potential of outer membrane vesicles (OMVs) for 
vaccination against shigellosis [31]. Here, we go further into characterizing the 
protective ability of OMVs harvested from a BEI-inactivated Shigella culture. Results 
demonstrated that the combination of BEI-FA was efficient for inactivation of Shigella, 
did not affect its immunogenic properties and, what´s more, confirm the potential of the 
OMVs as a valuable strategy vaccination against Shigellosis. 
 
 
 
2. Material and Methods 
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2.1. Bacterial strains and culture conditions: 
A clinical isolate of Shigella flexneri 2a (“Clínica Universidad de Navarra”, Pamplona, 
Spain) was used along the study of inactivation and OMV production. On the day 
previous to each experiment, S. flexneri originally isolated in Tryptone-Soya-Agar 
(Biomerieux) was seeded into Tryptone-Soya-Broth and incubated for 16 h at 37 °C 
with agitation to reach stationary phase. 
 
2.2 Inactivating agents: 
Phenol and formaldehyde were purchased from Panreac (Barcelona, Spain). 2-
bromoethylamine hydrobromide (BEA) from Sigma-Aldrich (St. Louis, MO USA) and 
Na-thiosulfate (Merck). All stock solutions of the chemicals were prepared by 
dissolving or diluting the chemicals to obtain the required concentrations using 
deionized water. Working solutions were freshly prepared and sterilized using 0.22 ȝm 
filters prior to each experiment  
BEI was prepared by cyclization of 0.1 M BEA (Sigma) in 0.175 M NaOH solution for 
one hour at room temperature following the method of Bahnemann [32]. The 
cyclization of 0.1 M 2-bromoethylamine into the active BEI form was confirmed by the 
change in the pH, from 12.7 to 8.7. The solution was freshly prepared prior to each 
experiment. Controls were performed with other commonly used treatments (phenol 0. 
5% v/v, 4 h) or heat (60 ºC, 30 min) and an untested culture was also included. 
Bacteria in stationary phase culture were dispensed into 50 ml and 500 ml aliquots. 
Different volumes of BEI or a combination of BEI –FA were added to each aliquot 
containing bacteria to obtain final BEI concentrations of 2 mM, 4 mM, 6 mM (see table 
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2). These suspensions were incubated at 37 °C with continuous stirring up to 24 h. At 
different time points of 1 h intervals, aliquots of 1,000 ȝl were directly spread onto TSA 
plates, incubated at 37 °C and inspected for growth during 7 days. The colonies were 
then counted to evaluate bactericidal activity. Full bactericidal activity was considered 
when no colonies appeared after 7 days incubation; in contrast, above one colony was 
considered incomplete bactericidal activity. 
The residual BEI was hydrolysed by the addition of 1 M sterile Na-thiosulfate solution 
at 10% of the volume of the BEI used before discarding.  
 
2.3 Activation of Ipa proteins secretion by Congo Red.  
Ipa proteins release was induced using a Congo Red secretion assay [33]. Exponential-
phase bacteria were harvested, suspended in 10 ȝM Congo Red (Panreac)/PBS, and 
incubated at 37 ºC for 30 min. Then, cultures were treated with the inactivating agent. 
Following incubation, bacteria were pelleted by centrifugation at 14,000 × g for 15 min 
at 20 °C, and supernatants were collected, filtered using a 0.22 ȝm pore diameter filter 
and analysed by SDS-PAGE and immunoblotting [31] using monoclonal antibodies 
against IpaB and IpaC (kindly provided by A. Phalipon, Institut Pasteur). 
 
 
2.4 Cell integrity assessment after inactivation. 
 Cells were grown to stationary phase in liquid Tryptic soy broth and inactivated with 
BEI-FA, phenol (0.5%, 4 h) or heat (60 ºC, 30 min). Then, cells were harvested by 
centrifugation (6,000 × g, 10 min). Proteins on supernatant were precipitated with 
tricholoroacetic acid and analysed by SDS-PAGE and silver staining for proteins, as 
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described elsewhere [31]. 
 
2.5 Preparation and characterization of OMV.  
Cells were grown to stationary phase in tryptic soy broth, inactivated with BEI-FA, and 
after that, OMVs were recovered from supernatant as previously described [31]. 
Supernatant was purified by diafiltration via a 300-kDa tangential filtration 
concentration unit (Millipore). Then, the retentate was frozen. Final product was 
recovered by centrifugation at 40,000 × g, 2 h and finally liophylized. Total protein 
content was determined by the method of Lowry, with bovine serum albumin as 
standard. Lypopolysaccharide (LPS) content was determined by the Purpald assay 
[34;35]. Antigenic complexes were analyzed by SDS-PAGE and silver staining for LPS 
and immunoblotting, using polyclonal pool sera from rabbit hyperimmunized with S. 
flexneri [36] or monoclonal antibodies against IpaC (kindly provided by A. Phalipon, 
Institut Pasteur) or OmpA.  OMVs release and antigenic complex were examined by 
transmission electron microscopy (Zeiss LIBRA® 120 EFTEM). 
 
2.6. Active immunization and experimental infection in mice: 
All mice were treated in accordance with institutional guidelines for treatment of 
animals (Protocol 081-11 approved December 16, 2011 by the Ethical Comittee for the 
Animal Experimentation, CEEA, of the University of Navarra). Nine-week-old BALB/c 
mice [37] were separated in randomized groups of 10 animals and immunized with one 
dose of free OMVs (20 µg) by the nasal route (3 ȝl per nostril). Experimental infection 
was performed on day 35 post immunization intranasally with a lethal dose of 1×107 
UFCs of Shigella flexneri 2a grown to logarithmic phase and suspended in 20 µL of 
prewarmed PBS. The number of dead mice after challenge was recorded daily. Mice 
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weight was determined at different time points post-challenge. 
 
2.7. Statistics  
Statistical analyses were performed using GraphPad Prism 5 for Mac OS X. The 
Kaplan-Meyer curves were used for analysis of the protection experiment.  
 
3. RESULTS 
 
3.1 Effect of binary ethylenimine as bactericidal agent. 
The inactivating effect of binary ethylenimine alone (BEI) or in combination with 
formaldehyde (BEI-FA) was studied in vitro against stationary phase cultures of S. 
flexneri (Table 1). Results indicate that BEI was effective against Shigella in small 
volume cultures (50 mL). For larger volumes (500 mL) in which BEI alone was not as 
efficient, the combination with a small amount of formaldehyde (0.06% v/v) led to the 
complete inactivation of the Shigella inocula. 
 
3.2. Cell integrity assessment after inactivation: 
The efficiency of the chemical agent was rated not only for its bactericidal activity, but 
also for the lack of effects on the structural integrity on the bacterial cell. For this 
purpose, a batch of Shigella culture was distributed in aliquots in different flasks and 
treated with BEI-FA reagent (BEI 6mM-FA 0.06%, 4h). Controls performed with other 
commonly used treatments (phenol 0.5% v/v, 4 h) or heat (60 ºC, 30 min) and an 
untreated culture, were also included. After inactivation, supernatants were analyzed by 
SDS-PAGE and silver staining, suggesting that BEI-FA did not affect the cellular 
integrity since no proteins were found in BEI-FA supernatant culture (Fig. 1). In 
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contrast, phenol and heat had a marked disrupting effect referring to the untreated 
control according to the wide range of proteins observed in the supernatants (Fig. 1). 
 
3.3. Ipa proteins antigenic conservation after inactivation.  
In order to evaluate the potential value of BEI-FA inactivation method, the effect on the 
Ipa proteins, important virulence factors of Shigella, was studied. After induction of the 
secretion of Ipa proteins with Congo red, bacteria were treated with BEI-FA. Ipa 
proteins were identified by SDS-PAGE and immunoblotting in the supernatant of the 
inactivated bacterial culture (Fig. 2A). As shown in Figure 2, BEI-FA did not affect the 
antigenicity of Ipa proteins. Two bands corresponding to IpaB and IpaC were identified 
using monoclonal antibodies against these proteins (Fig. 2B). 
 
 
3.4. Isolation of OMVs after BEI-FA inactivation.  
OMVs were harvested from supernatants of stationary phase S. flexneri culture 
inactivated by BEI-FA. OMV released from the outer surface of S. flexneri (Fig. 3A) 
appeared as bilayer spherical structures with an average diameter of 52.0 ± 17.6 nm 
(Figure 3B). SDS-PAGE and immunoblotting analysis indicated that major 
immunodominant proteins such as OmpA [38], porins (37-38 kDa) [39], IpaB and Ipa C 
(42 KDa) were present in the extract (Fig. 4). Immunoblotting using Mab against IpaC 
and OmpA confirmed their identity (data not shown). 
In order to evaluate the immunogenicity and protection conferred by OMVs vaccine, 
mice were immunized with OMV (20 Pg) by nasal route. On day 35 after immunization, 
mice were challenged with a lethal dose of S. flexneri via intranasal route and monitored 
for survival over 15 days. Immunization with OMVs isolated after BEI-FA inactivation 
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of S. flexneri culture conferred full protection (Fig. 5) and no clinical manifestations or 
changes in body weight were observed after challenge (data non shown). Furthermore, 
no symptoms were observed after immunization. 
 
 
4. DISCUSSION 
Current vaccines strategies against Shigella can be grouped into two fundamental 
approaches: live-attenuated vaccines and nonliving vaccines [6-8]. While the essential 
concern regarding live attenuated candidates is to find the appropriate balance between 
immunogenicity and acceptable side effects, different scenery appears for inactivated 
whole cell or subunit vaccines. The success of these kinds of vaccines depends, in part, 
on preparing the bacteria in a manner that, after inactivation, the immunogenicity and 
native structural epitopes essential for protection are preserved. Several methods have 
been used to inactivate Shigella cultures for eventual vaccine evaluation. Usually, 
methods include the use of formaldehyde, heat or acetone. However, most of these 
agents cause membrane damage and may lead to antigenic denaturising [40-42]. In line 
with this, we have previously described the use of binary ethylenimine for inactivation 
of Shigella cells [31]. In the former study, we used an acellular vaccine against 
shigellosis based on outer membrane vesicles (OMVs) obtained from supernatants of 
BEI-inactivated Shigella cultures. BEI is an aziridine compound reacting with nucleic 
acids, which has been shown elsewhere to efficiently inactivate several RNA and DNA 
viruses in vaccine production [22]. For example, BEI is widely used in the preparation 
of the Foot and Mouth virus vaccine, with about 500 million doses administered in 
cattle annually without any described drawbacks [22;32]. Given that BEI reacts by 
intercalation on nucleic acids, it was expected that this compound would not disrupt 
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membrane surface [16;43]. In the present study, we make an in-depth understanding of 
the potential of BEI to inactivate Shigella cells in order to offer an achievable 
implement into non-living vaccine production.  
Our results demonstrate that the combination of BEI-FA (BEI, 6 mM containing 
formaldehyde, 0.06 %, 6 h) inactivated completely the Shigella inocula used (Table 1). 
The combination with formaldehyde resulted in a synergistic effect between the two 
agents previously described by Bahneman [22]. Moreover, it is described that the 
stability of vaccines increased significantly when, after inactivation with aziridine, the 
antigen was treated with formaldehyde [44]. At this point, it is important to highlight 
that the concentration of formaldehyde used was 0.06%, a much lower concentration 
than the generally used of 1-3% [19;20]. This low concentration of formaldehyde 
implies a negligible disturbing effect on membrane surface or antigenicity. In fact, as 
Figure 1 shows, the absence of new released proteins in culture supernatant after BEI-
FA treatment suggests that the membrane structure is maintained. Moreover, antigenic 
properties were also preserved. To this respect, of particular interest are the Ipa 
(Invasion antigen plasmid) proteins. They are relevant effectors on the pathogenesis and 
are highly conserved among Shigella species. Four types, named Ipa (A-D), have being 
described as main immunogenic proteins of Shigella [45;46]. After the induction of the 
secretion of Ipa proteins by Congo red, cultures were treated with BEI-FA. Results 
showed that BEI-FA did not have denaturing effects on Ipa proteins antigenicity (Fig. 
2). This is an important aspect since Ipa proteins are very labile to antigenic 
conformation changes [47]. In view of these results, BEI-FA method fulfilled the two 
basic seek requirements: firstly, the complete, fast and reliable inactivation of Shigella; 
secondly, the lack of disruption of the membrane surface or any denaturing effect. To 
this respect, it is worthy to mention that to our knowledge, although some studies have 
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been carried out using BEI [22;48], this is the first report describing its use against 
Shigella.  
Finally, in order to study the protective immunogenic of an antigenic complex obtained 
from Shigella BEI-inactivated cells, we focused on OMVs. Shigella releases OMVs as 
spherical lipid bilayer conformed by LPS, OMP and Ipa proteins [49]. These are 
considered as main protective antigens against shigellosis [6;8]. Accordingly, current 
subcellular strategies include these antigens in their composition. For instance, LPS,  
IpaB and IpaC are contained in the “Invaplex 50”, a subcellular vaccine candidate 
against shigellosis that is already under phase II of clinical trials [8]. Other approaches 
include IpaB and IpaD obtained by molecular recombinant techniques [50]. Results 
demonstrated that BEI treatment did not affect immunogenic of OMV antigens. In fact, 
one single nasal dose of OMV was able to fully protect mice against a lethal dose of S. 
flexneri 2a, confirming previous results [31]. It is important to highlight that our 
proposal aims the utilization of these antigens maintaining their membrane environment 
and native conformation and hence, the original epitopes repertoire. Furthermore, it has 
been described that the “OMV delivery system” may act as a protective environment for 
delivery of soluble antigens [51] and besides, that the presentation of antigens under this 
OMV-context is expected to be more efficient [52]. To sum up, BEI inactivation comes 
into sight as a useful method for inactivation of bacteria with no alteration of antigenic 
properties as well as leading to optimal immunogenic condition. From this valuable role 
regarding vaccination, inactivation with BEI-FA emerges as a good safety implement 
for non-living Shigella vaccines.  
 
5. Conclusions 
 13 
 
A combination of binary ethylenimine and formaldehyde (BEI-FA) demonstrated to be 
effective for the inactivation of Shigella cells. BEI-FA did also maintain the antigenic 
properties of Ipa proteins and OMV complex. Results showed that OMVs obtained after 
BEI-FA treatment kept antigenicity and immunogenicity, confirming their potential for 
nasal vaccination against S. flexneri. 
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Table 1.  Bactericidal effect of binary ethylenimine (BEI) against Shigella flexneri. 
Aliquots of stationary phase cultures of S. flexneri were treated with BEI alone or in 
combination with formaldehyde (BEI-FA) 
Chemical 
treatment time 
(h)
Culture 
Volume 
(mL)
bactericidal activity1   
(minimal treatment time)
2-24 50 Complete (6 h)
2-24 500 Incomplete
2-24 50 Complete (6 h)
2-24 500 Incomplete
2-24 50 Complete (4 h)
2-24 500 Complete (16 h)
2-24 50 Complete (4 h)
2-24 500 Complete (6 h)
BEI -FA 4 mM (0.04% FA)
BEI -FA 6 mM (0.06% FA)
Inactivating agent
BEI 4 mM
BEI 6 mM
 
1 Complete: full bactericidal activity (no growth after 7 days incubation on TSA plates); 
Incomplete: null or partial bactericidal activity at the indicated incubation time. 
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Figure 1. Comparative analysis of Shigella flexneri supernatants after inactivation. 
SDS-PAGE with silver staining for proteins of Shigella flexneri culture supernantant 
after (1) no treatment or (2) binary ethylenimine-formaldehyde (BEI-FA): [BEI (6mM)- 
FA (0.06%)], (3) Phenol 0.5% or (4) heat (60 ºC, 15 min) treatments. Standard 
molecular weight markers are indicated. 
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Figure 2. Antigen conservation of Ipa proteins after inactivation. Bacteria 
were suspended in PBS at a concentration of 1.0108 CFU/ml and incubated at 
37°C in the absence (lane 1) or presence (lane 2) of 10 ȝM Congo red. After 30 min 
of incubation, the inactivating agent [BEI (6mM)- FA (0.06%)] was added. Samples 
were centrifuged and supernatant extracts were subjected to SDS-PAGE with silver 
staining (A) and immunoblotting (B) with monoclonal antibodies against IpaB (lane 
3) or IpaC (lane 4). Molecular weight markers and the identity of Ipa proteins are 
indicated. 
 
 
 
Figure 3: Transmission electron microscopy showing outer membrane vesicles 
(OMVs) released from Shigella flexneri 2a (A). Panel B shows negative staining of  
OMVs collected from BEI-FA inactivated Shigella culture followed by diafiltration as  
purification process. 
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Figure 4. Analysis of Shigella flexneri outer membrane vesicles (OMV) collected 
from BEI treated cells. SDS-PAGE with silver staining of LPS form outer membrane 
vesicles (OMVs) (lane 1). SDS-PAGE with Coomassie Blue staining of OMVs (lane 2). 
SDS-PAGE and immunoblotting of OMVs using a pool of sera from rabbit 
hyperimmunized with whole cells from S. flexneri (lane 3) Molecular weight markers 
and identity of some bands are indicated on the left. 
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Figure 5. Protection study against Shigella flexneri experimental infection. BALB/c 
mice (20 ±1 g) were immunized oncewith 20 ȝg of outer membrane vesicles (OMVs) 
by nasal route. An extra group was included as non-immunized control. At day 35 after 
immunization, all groups received an intranasal lethal challenge of 1.0 u 107 
UFC/mouse of S. flexneri 2a (clinical isolate). Graphs indicate the percentage of mice 
that survived the infective challenge at the indicated days after immunization (*, 
P<0.01, Logrank test) 
 
 
 
 
 
 
 
